Avalyn Pharma Inc. (AVLN)
NASDAQ · Healthcare
$28.63+1.17%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.25B
- P/E ratio
- —
- EPS
- —
- Volume
- 195,216
- 52-week high
- —
- 52-week low
- —
- Open
- $28.31
- Day high
- $29.02
- Day low
- $27.84
Financial highlights
Annual financials for Avalyn Pharma Inc. are being compiled and will appear here soon.
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
- CEO
- Lyn Baranowski
- Employees
- 50
- Country
- US
- IPO date
- Apr 30, 2026
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Avalyn Pharma Inc.'s stock price today?
- AVLN is trading at $28.63 as of Jul 20, 2026.
- What is Avalyn Pharma Inc.'s market cap?
- Avalyn Pharma Inc. (AVLN) has a market capitalization of $1.25B.
- What sector is Avalyn Pharma Inc. in?
- Avalyn Pharma Inc. operates in the Healthcare sector.